MASH efficacy
Evaluate candidate activity in diet-induced metabolic liver-disease settings using protocol-defined efficacy endpoints.
METABOLIC LIVER DISEASE MODEL
MASH (NASH) Preclinical Models
Diet-induced MASH/NASH models, including MCD-, AMLN-, and HFD/STZ-based study formats, support metabolic liver-disease pharmacology with histology, fibrosis, biomarker, and PK/PD endpoints.
Diet format, species or strain, induction duration, baseline disease state, treatment window, and tissue-readout package are confirmed for each program.
MODEL OVERVIEW
Diet-induced MASH models for efficacy and liver-disease phenotyping.
MASH/NASH studies can be configured around confirmed diet- or diet/chemical-induced formats, including MCD, AMLN, and HFD/STZ approaches, and aligned to the candidate mechanism, treatment schedule, disease stage, and required tissue or PK/PD outputs.
Therapeutic areaMASH, Metabolic liver disease
SpeciesRodent
Model formatMCD, AMLN, HFD/STZ
Typical useEfficacy, Histology, Fibrosis
TYPICAL APPLICATIONS
What this model can support.
Steatosis & inflammation
Assess liver fat accumulation, inflammatory changes, and related histopathology according to the selected model format.
Fibrosis assessment
Incorporate fibrosis-focused staining, scoring, or other tissue readouts when required by the development question.
PK/PD & biomarkers
Integrate systemic or liver exposure with biochemical, molecular, and mechanism-linked pharmacodynamic measurements.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Liver histology
Protocol-defined assessment of steatosis, inflammation, ballooning, and composite histopathology where applicable.
Fibrosis
Fibrosis staining, scoring, and related tissue measurements selected for the study objective.
Biochemical markers
Serum and tissue biomarkers relevant to liver injury, lipid metabolism, inflammation, or the candidate mechanism.
PK & exposure
Plasma or liver exposure and exposure-response measurements when incorporated into the program.
Final species, strain, diet composition, induction period, disease-entry criteria, histology package, and study timeline are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- MCD, AMLN, HFD/STZ, or another confirmed model format
- Species, strain, and diet composition
- Induction duration and baseline disease criteria
- Treatment timing, route, and duration
- Histology and fibrosis assessment plan
- Biomarker, tissue, and PK/PD requirements
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a MASH study.Required fields are marked with an asterisk(*).